Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of MenACWY-TT formulations in young children
2004-003768-32Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2004
- Modality
- Vaccines & Immunotherapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine, MenC-CRM197 conjugate vaccine and meningococcal ACYW135 vaccine in meningococcal disease (6 arms), sponsored by GSK. Primary endpoints: Immunogenicity one month after first vaccine dose, Reactogenicity and 1 more. Started Dec 2004; status: completed.
02
Drugs
meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccineMenC-CRM197 conjugate vaccinemeningococcal ACYW135 vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2004-003768-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003768-32.